ProMIS Neurosciences (PMN) Other Non Operating Income (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Other Non Operating Income came in at $400523.0 in Q1 2026, up 257.0% YoY from $112192.0 in Q1 2025, and up 333.28% on a QoQ basis from $92439.0 in Q4 2025.
ProMIS Neurosciences (PMN) Other Non Operating Income (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Other Non Operating Income data on file, last reported at $400523.0 in Q1 2026.
- Quarterly Other Non Operating Income rose 257.0% year-over-year to $400523.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $730900.0 (up 20.63% YoY) and the FY2025 annual result came in at $442569.0, down 29.32% from the prior year.
- Other Non Operating Income grew to $400523.0 in Q1 2026, from $92439.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $400523.0 in Q1 2026 to a low of $10774.0 in Q1 2022.
- A 5-year average of $115864.9 and a median of $92439.0 in 2025 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income soared 5174.14% — and 2025, when it tumbled 59.25%.
- Tracing PMN's Other Non Operating Income over 5 years: stood at $52610.0 in 2022, then soared by 257.03% to $187833.0 in 2023, then climbed by 20.77% to $226840.0 in 2024, then plunged by 59.25% to $92439.0 in 2025, then soared by 333.28% to $400523.0 in 2026.
- The last three Other Non Operating Income figures came in at $400523.0 (Q1 2026), $92439.0 (Q4 2025), and $170306.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 536,743.00 |
| Mar 31, 2026 | 400,523.00 |
| Dec 31, 2025 | 92,439.00 |
| Sep 30, 2025 | 170,306.00 |
| Jun 30, 2025 | 67,632.00 |
| Mar 31, 2025 | 112,192.00 |
| Dec 31, 2024 | 226,840.00 |
| Sep 30, 2024 | 235,912.00 |
| Jun 30, 2024 | 30,962.00 |
| Mar 31, 2024 | 132,470.00 |
| Dec 31, 2023 | 187,833.00 |
| Sep 30, 2023 | 113,286.00 |
| Jun 30, 2023 | 30,878.00 |
| Mar 31, 2023 | 52,905.00 |
| Dec 31, 2022 | 52,610.00 |
| Sep 30, 2022 | 35,853.00 |
| Jun 30, 2022 | 16,288.00 |
| Mar 31, 2022 | 10,774.00 |
| Dec 31, 2021 | 11,236.00 |
| Sep 30, 2021 | 4,052.00 |